
Translational Oncology, Journal Year: 2024, Volume and Issue: 48, P. 102061 - 102061
Published: July 27, 2024
Language: Английский
Translational Oncology, Journal Year: 2024, Volume and Issue: 48, P. 102061 - 102061
Published: July 27, 2024
Language: Английский
Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 2975 - 2975
Published: Aug. 27, 2024
Malignant gliomas present great difficulties in treatment, with little change over the past 30 years median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing formation new vasculature (antiangiogenic treatments) or destroying formed tumor (vascular disrupting agents) show promise. This study summarizes existing knowledge regarding processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses activation redundant proangiogenic pathways, heightened cell invasion metastasis, induced hypoxia, creation vascular mimicry channels, regulation immune microenvironment. Subsequently, we explore potential strategies overcome this resistance, such as combining other methods, personalizing treatments for each patient, focusing on therapeutic targets, incorporating immunotherapy, utilizing drug delivery systems based nanoparticles. Additionally, would like discuss limitations methods future directions enhance beneficial effects patients GBM. Therefore, review aims research outcome GBM provide a more promising opportunity thoroughly exploring mechanisms investigating novel strategies.
Language: Английский
Citations
10Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106761 - 106761
Published: March 1, 2025
Language: Английский
Citations
0BIO Integration, Journal Year: 2025, Volume and Issue: 6(1)
Published: Jan. 1, 2025
Lipid-based Nanoparticles (LBNPs) have emerged as a transformative approach in cancer treatment, offering innovative drug delivery solutions that enhance therapeutic efficacy while minimizing adverse effects. By exploring the characterization, classification, synthesis, targeting strategies, and advantages of LBNPs, this study highlights how LBNPs been used to overcome limitations traditional chemotherapy improve patient outcomes. As nanotechnology revolutionizes therapy, emergence promising strategy for targeted has led optimism regarding future treatment. This review extensively assesses structure, categories, production methods, benefits, recent advancements treating cancer. It also current challenges possible directions. is aimed at providing comprehensive understanding LBNPs’ potential therapy. Liposomes, nanostructured lipid carriers, solid nanoparticles, lipid-polymer hybrid nanoparticles are all types each with unique features interest These particles can be synthesized through various procedures, such bulk nanoprecipitation, solvent-based emulsification, or microfluidics. Passive systems, active responsive platforms direct tumors. Consequently, provide an improved release pattern minimizes side effects enhancing efficacy. With combination offer hopeful Continued research expected outcomes overall quality life care.
Language: Английский
Citations
0Translational Oncology, Journal Year: 2024, Volume and Issue: 48, P. 102061 - 102061
Published: July 27, 2024
Language: Английский
Citations
0